Last reviewed · How we verify
QLS1128 A-Dose 1~5 and Ritonavir
QLS1128 A-Dose 1~5 and Ritonavir is a Small molecule drug developed by Qilu Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | QLS1128 A-Dose 1~5 and Ritonavir |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS1128 A-Dose 1~5 and Ritonavir CI brief — competitive landscape report
- QLS1128 A-Dose 1~5 and Ritonavir updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about QLS1128 A-Dose 1~5 and Ritonavir
What is QLS1128 A-Dose 1~5 and Ritonavir?
QLS1128 A-Dose 1~5 and Ritonavir is a Small molecule drug developed by Qilu Pharmaceutical Co., Ltd..
Who makes QLS1128 A-Dose 1~5 and Ritonavir?
QLS1128 A-Dose 1~5 and Ritonavir is developed by Qilu Pharmaceutical Co., Ltd. (see full Qilu Pharmaceutical Co., Ltd. pipeline at /company/qilu-pharmaceutical-co-ltd).
What development phase is QLS1128 A-Dose 1~5 and Ritonavir in?
QLS1128 A-Dose 1~5 and Ritonavir is in Phase 1.